Healios KK
TSE:4593
Intrinsic Value
Healios KK engages in the research, development, and sale of cellular and regenerative medicine. [ Read More ]
The intrinsic value of one Healios KK stock under the Base Case scenario is 251.57 JPY. Compared to the current market price of 152 JPY, Healios KK is Undervalued by 40%.
Valuation Backtest
Healios KK
Run backtest to discover the historical profit from buying and selling Healios KK stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Healios KK
Current Assets | 7.7B |
Cash & Short-Term Investments | 6.7B |
Receivables | 324m |
Other Current Assets | 637m |
Non-Current Assets | 7.5B |
Long-Term Investments | 2.7B |
PP&E | 674m |
Intangibles | 4.1B |
Other Non-Current Assets | 2m |
Current Liabilities | 5.2B |
Accounts Payable | 229m |
Other Current Liabilities | 4.9B |
Non-Current Liabilities | 6.1B |
Long-Term Debt | 4B |
Other Non-Current Liabilities | 2.2B |
Earnings Waterfall
Healios KK
Revenue
|
121m
JPY
|
Cost of Revenue
|
-13m
JPY
|
Gross Profit
|
108m
JPY
|
Operating Expenses
|
-3.5B
JPY
|
Operating Income
|
-3.4B
JPY
|
Other Expenses
|
-444m
JPY
|
Net Income
|
-3.8B
JPY
|
Free Cash Flow Analysis
Healios KK
Profitability Score
Profitability Due Diligence
Healios KK's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Healios KK's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Healios KK's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Score
Healios KK's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Healios KK
According to Wall Street analysts, the average 1-year price target for Healios KK is 308.55 JPY with a low forecast of 141.4 JPY and a high forecast of 420 JPY.
Shareholder Return
Price
Healios KK
Average Annual Return | -27.57% |
Standard Deviation of Annual Returns | 42.36% |
Max Drawdown | -95% |
Market Capitalization | 13.7B JPY |
Shares Outstanding | 90 130 022 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.
Contact
IPO
Employees
Officers
The intrinsic value of one Healios KK stock under the Base Case scenario is 251.57 JPY.
Compared to the current market price of 152 JPY, Healios KK is Undervalued by 40%.